Conway Sarah E, Pua Danielle Kei A, Holroyd Kathryn B, Galetta Kristin, Bhattacharyya Shamik
Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mult Scler. 2023 Mar;29(3):471-474. doi: 10.1177/13524585221117949. Epub 2022 Aug 11.
There is concern that immune checkpoint inhibitors (ICPIs) can provoke relapses in people with multiple sclerosis (pwMS).
Analyze outcomes of pwMS who received ICPI treatment for malignancy.
We electronically identified pwMS who received ICPI treatment at Mass General Brigham hospital system. We retrospectively obtained information about patients' MS, cancer, treatment, and outcomes.
Sixteen patients were identified with an average (standard deviation (SD)) age of 67.4 (11.9) years. Eleven (68.8%) had no relapses since MS diagnosis. None had MS relapses after ICPI treatment or new MS lesions.
ICPI use was not associated with increased clinical disease activity in this cohort of older patients with inactive MS.
人们担心免疫检查点抑制剂（ICPIs）会引发多发性硬化症（pwMS）患者复发。
分析接受ICPI治疗恶性肿瘤的pwMS患者的结局。
我们通过电子方式识别在麻省总医院布莱根医院系统接受ICPI治疗的pwMS患者。我们回顾性获取了患者的多发性硬化症、癌症、治疗及结局的相关信息。
共识别出16例患者，平均（标准差[SD]）年龄为67.4（11.9）岁。11例（68.8%）自多发性硬化症诊断后未复发。接受ICPI治疗后无人出现多发性硬化症复发或新发多发性硬化症病灶。
在这一队列病情稳定的老年多发性硬化症患者中，使用ICPI与临床疾病活动度增加无关。
